Ixekizumab for treatment of moderate-to-severe plaque psoriasis: 12-week results from a phase 3 study (UNCOVER-1)

被引：0
|
作者：
Gordon, Kenneth [1 ]
Blauvelt, Andrew [2 ]
Langley, Richard [3 ]
Luger, Thomas [4 ]
Ohtsuki, Mamitaro [5 ]
Cameron, Gregory S. [6 ]
Braun, Daniel K. [6 ]
Erickson, Janelle [6 ]
Zhao, Fangyi [6 ]
Shrom, David S. [6 ]
Osuntokun, Olawale O. [6 ]
Heffernan, Michael P. [6 ]
Nickoloff, Brian [6 ]
Leonardi, Craig [7 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA
[2] Oregon Hlth & Sci Univ, Sch Med, Dept Dermatol, Portland, OR 97201 USA
[3] Dalhousie Univ, Dept Med, Halifax, NS, Canada
[4] Univ Munster, Dept Dermatol, D-48149 Munster, Germany
[5] Jichi Med Univ, Dept Dermatol, Shimotsuke, Japan
[6] Eli Lilly & Co, Indianapolis, IN 46285 USA
[7] St Louis Univ, Dept Dermatol, Sch Med, St Louis, MO USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2015年 / 135卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P029
引用
收藏
页码：S6 / S6
页数：1
相关论文
共 50 条
  • [1] Maintenance of Efficacy Results from UNCOVER-1: A Phase 3 Trial of Ixekizumab for Moderate-to-Severe Plaque Psoriasis
    Leonardi, C.
    Leutz, A.
    Blauvelt, A.
    Langley, R. G.
    Luger, T.
    Ohtsuki, M.
    Cameron, G. S.
    Erickson, J.
    Zhao, F.
    Shrom, D. S.
    Braun, D.
    Osuntokun, O. O.
    Heffernan, M.
    Nickoloff, B. J.
    Gordon, K.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 4 - 4
  • [2] Maintenance of efficacy results from UNCOVER-1: A phase 3 trial of ixekizumab for moderate-to-severe plaque psoriasis
    Leonardi, Craig
    Blauvelt, Andrew
    Langley, Richard
    Luger, Thomas
    Ohtsuki, Mamitaro
    Cameron, Gregory S.
    Braun, Daniel
    Erickson, Janelle
    Zhao, Fangyi
    Shrorn, David S.
    Osuntokun, Olawale O.
    Heffernan, Michael P.
    Nickoloff, Brian
    Gordon, Kenneth
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S16 - S16
  • [3] Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 12-week results from a phase 3 study
    Rui, Wenlong
    Li, Xia
    Zheng, Jie
    Pan, Weili
    Zheng, Min
    Lu, Yan
    Li, Fuqiu
    Ding, Yangfeng
    Zhang, Jianzhong
    Li, Hongying
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB55 - AB55
  • [4] Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3
    Egeberg, Alexander
    Wu, Jashin J.
    Korman, Neil
    Solomon, James A.
    Goldblum, Orin
    Zhao, Fangyi
    Mallbris, Lotus
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (01) : 104 - +
  • [5] A phase 3 trial comparing ixekizumab with placebo and etanercept for moderate-to-severe plaque psoriasis: Results from the 12 week induction period of UNCOVER 3
    Griffiths, Christopher E.
    Reich, Kristian
    Lebwohl, Mark
    Van de Kerkhof, Peter
    Paul, Carle
    Menter, Alan
    Carlier, Hilde
    Cameron, Gregory
    Erickson, Janelle
    Zhang, Lu
    Secrest, Roberta
    Ball, Susan
    Braun, Daniel
    Osuntokun, Olawale
    Heffernan, Michael
    Nickoloff, Brian
    Papp, Kim
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S17 - S17
  • [6] Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)
    Reich, Kristian
    Leonardi, Craig
    Lebwohl, Mark
    Kerdel, Francisco
    Okubo, Yukari
    Romiti, Ricardo
    Goldblum, Orin
    Dennehy, Ellen B.
    Kerr, Lisa
    Sofen, Howard
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2017, 28 (04) : 282 - 287
  • [7] Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1)
    Imafuku, Shinichi
    Torisu-Itakura, Hitoe
    Nishikawa, Atsushi
    Zhao, Fangyi
    Cameron, Gregory S.
    [J]. JOURNAL OF DERMATOLOGY, 2017, 44 (11): : 1285 - 1290
  • [8] A phase 3 trial comparing ixekizumab with placebo and etanercept for moderate-to-severe plaque psoriasis: Results from the 12 week induction period of UNCOVER-2
    Griffiths, Christopher E.
    Reich, Kristian
    Lebwohl, Mark
    Van de Kerkhof, Peter
    Paul, Carle
    Menter, Alan
    Carlier, Hilde
    Cameron, Gregory
    Erickson, Janelle
    Zhang, Lu
    Secrest, Roberta
    Ball, Susan
    Braun, Daniel
    Osuntokun, Olawale
    Heffernan, Michael
    Nickoloff, Brian
    Papp, Kim
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S17 - S17
  • [9] A Phase 3 Trial Comparing Ixekizumab with Placebo and Etanercept for Moderate-to-Severe Plaque Psoriasis: Results from the 12 Week Induction Period of UNCOVER-2
    Griffiths, C. E. M.
    Leutz, A.
    Reich, K.
    Lebwohl, M.
    van de Kerkhof, P.
    Paul, C.
    Menter, A.
    Cameron, G. S.
    Erickson, J.
    Zhang, L.
    Secrest, R.
    Ball, S.
    Braun, D.
    Osuntokun, O. O.
    Heffernan, M.
    Nickoloff, B. J.
    Papp, K.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 3 - 3
  • [10] The impact of ixekizumab treatment on health-related quality of life in patients with moderate-to-severe psoriasis: results from UNCOVER-1
    Augustin, M.
    Gordon, K.
    Nikai, E.
    Edson-Heredia, E.
    Zhu, B.
    Goldblum, O. M.
    Carlier, H.
    Langley, R. G.
    [J]. EXPERIMENTAL DERMATOLOGY, 2016, 25 (03) : E9 - E9
12345